[go: up one dir, main page]

ATE526981T1 - Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen - Google Patents

Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen

Info

Publication number
ATE526981T1
ATE526981T1 AT01947222T AT01947222T ATE526981T1 AT E526981 T1 ATE526981 T1 AT E526981T1 AT 01947222 T AT01947222 T AT 01947222T AT 01947222 T AT01947222 T AT 01947222T AT E526981 T1 ATE526981 T1 AT E526981T1
Authority
AT
Austria
Prior art keywords
vegf
homologues
neurological disorders
treat neurological
disease
Prior art date
Application number
AT01947222T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Bert Oosthuyse
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Life Sciences Res Partners Vzw filed Critical Vib Vzw
Application granted granted Critical
Publication of ATE526981T1 publication Critical patent/ATE526981T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
AT01947222T 2000-04-12 2001-04-12 Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen ATE526981T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00201325 2000-04-12
EP00203382 2000-09-29
PCT/EP2001/004293 WO2001076620A2 (en) 2000-04-12 2001-04-12 Use of vegf and homologues to treat neuron disorders

Publications (1)

Publication Number Publication Date
ATE526981T1 true ATE526981T1 (de) 2011-10-15

Family

ID=26072122

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01947222T ATE526981T1 (de) 2000-04-12 2001-04-12 Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen

Country Status (10)

Country Link
US (5) US7226908B2 (de)
EP (3) EP2295070B1 (de)
AT (1) ATE526981T1 (de)
AU (2) AU2001268968B2 (de)
CA (3) CA2404616C (de)
CY (3) CY1112126T1 (de)
DK (3) DK2295070T3 (de)
ES (3) ES2551160T3 (de)
PT (3) PT2295070E (de)
WO (1) WO2001076620A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226908B2 (en) * 2000-04-12 2007-06-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of VEGF and homologues to treat neuron disorders
ATE378056T1 (de) * 2001-08-10 2007-11-15 Imclone Systems Inc Medizinische verwendung von stammzellen, die vegfr-1 exprimieren
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
WO2005030240A2 (en) * 2003-09-23 2005-04-07 Ludwig Institute For Cancer Research Vege-cor vege-d materials and methods for stimulation of neural stem cells
ATE478678T1 (de) * 2004-05-27 2010-09-15 Vib Vzw Behandlung von amyotrohper lateralsklerose
US20070021421A1 (en) * 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
WO2007023479A2 (en) * 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
GB0803912D0 (en) * 2008-02-29 2008-05-07 Univ Bristol Novel Uses of VEGFxxxb
ES2376930B1 (es) * 2009-02-05 2013-01-24 Universidad Del Pais Vasco Método para el tratamiento de enfermedades neurodegenerativas.
EP2456784B1 (de) 2009-07-24 2017-01-11 Advanced Accelerator Applications S.A. Verbindungen als modulatoren der vegf-aktivität und ihre verwendung
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
US20210154270A1 (en) * 2018-04-12 2021-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
WO2023214189A1 (en) * 2022-05-05 2023-11-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and composition for treating neurodegenerative disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013780A (en) 1957-12-09 1961-12-19 Shell Oil Co Gas-liquid contacting apparatus with shutter trays
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
ATE309360T1 (de) 1994-03-08 2005-11-15 Human Genome Sciences Inc Vaskularer endothelialer wachstumsfaktor 2
ES2232860T3 (es) 1996-02-21 2005-06-01 Us Gov Health & Human Serv Proteinas recombinantes de ribonucleasa.
US6013780A (en) 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5965363A (en) 1996-09-19 1999-10-12 Genetrace Systems Inc. Methods of preparing nucleic acids for mass spectrometric analysis
JP2002516607A (ja) 1997-01-17 2002-06-04 ローヌ−プーラン・ロレ・エス・アー 延髄運動ニューロン中へのアデノウイルス性ベクター媒介遺伝子転移
NZ314594A (en) 1997-04-14 1998-06-26 Patchett Ag Air Ltd A spray boom including outlet nozzle clearing means and actuators therefor
US6455283B1 (en) * 1998-03-17 2002-09-24 Genentech, Inc. Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
KR20010034576A (ko) * 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
EP1115877B1 (de) 1998-09-23 2009-01-14 Oxford Biomedica (UK) Limited Polynucleotidkonstrukte und ihre verwendungen
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2365434A1 (en) * 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
AU6733400A (en) * 1999-08-30 2001-03-26 Sumitomo Pharmaceuticals Company, Limited Novel uses of semaphorin and vegf
US6930089B2 (en) * 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7226908B2 (en) 2000-04-12 2007-06-05 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of VEGF and homologues to treat neuron disorders
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
ATE478678T1 (de) * 2004-05-27 2010-09-15 Vib Vzw Behandlung von amyotrohper lateralsklerose

Also Published As

Publication number Publication date
WO2001076620A3 (en) 2001-12-20
ES2551160T3 (es) 2015-11-16
US20100041601A1 (en) 2010-02-18
CY1116933T1 (el) 2017-04-05
US7592314B2 (en) 2009-09-22
AU6896801A (en) 2001-10-23
PT2277528E (pt) 2015-02-05
CY1116296T1 (el) 2017-02-08
CA2654413A1 (en) 2001-10-18
US20080032314A1 (en) 2008-02-07
CY1112126T1 (el) 2015-11-04
US20030105018A1 (en) 2003-06-05
ES2528217T3 (es) 2015-02-05
US20110288020A1 (en) 2011-11-24
CA2404616C (en) 2009-08-18
AU2001268968B2 (en) 2006-10-19
DK2295070T3 (en) 2015-11-16
US7226908B2 (en) 2007-06-05
EP2277528A2 (de) 2011-01-26
DK2277528T3 (en) 2015-01-26
PT2295070E (pt) 2015-12-07
EP2295070A1 (de) 2011-03-16
WO2001076620A2 (en) 2001-10-18
EP1272208B1 (de) 2011-10-05
US20070249539A1 (en) 2007-10-25
DK1272208T3 (da) 2011-10-31
EP1272208A2 (de) 2003-01-08
PT1272208E (pt) 2012-01-03
US7888322B2 (en) 2011-02-15
CA2404616A1 (en) 2001-10-18
EP2295070B1 (de) 2015-08-12
EP2277528A3 (de) 2011-03-02
EP2277528B1 (de) 2014-11-12
CA2659656A1 (en) 2001-10-18
CA2654413C (en) 2016-10-18
ES2372809T3 (es) 2012-01-26

Similar Documents

Publication Publication Date Title
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60138019D1 (de) Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
ATE125701T1 (de) Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten.
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
MY136718A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
DE60228988D1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
BR0314541A (pt) Tratamento de demência e doença de parkinson
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
ATE268599T1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272208

Country of ref document: EP